Common Fertility Drug Linked to Higher Miscarriage Risk

Think more treatment always means better odds? Not necessarily. New research out of Adelaide University suggests that piling on doses of clomiphene citrate—the long‑standing ovulation drug—may raise the chance of miscarriage and multiple births without boosting the likelihood of a live baby.

Clomiphene citrate has been a mainstay of infertility care since 1967 and remains on the World Health Organization’s list of essential medicines. It nudges the body into ovulation by altering estrogen signaling, and for many patients modest courses are enough to get results. For others, the path is bumpier: when a first cycle fails, clinicians may repeat cycles or increase doses, adding to a patient’s cumulative exposure over time.

The new analysis focused exactly on that accumulated exposure. Collaborating with researchers at Boston University and the U.S. Centers for Disease Control and Prevention and supported by the NHMRC, the Adelaide team reviewed 21,004 IVF embryo transfer cycles across the United States to see whether higher total doses changed pregnancy outcomes.

The patterns were hard to ignore. Women whose cumulative clomiphene intake reached 500–749 mg faced about a 12% higher risk of miscarriage. At 750–999 mg the risk rose to roughly 38% above baseline. And among those exposed to at least 750 mg, the chance of twins or higher‑order multiples more than doubled.

Why does that matter beyond the numbers? Because infertility care doesn’t aim merely to create pregnancy; it aims to deliver one healthy baby at a time. Multiple pregnancies increase complications for both mother and child, and professional societies now prioritize approaches that reduce the likelihood of twins and triplets during assisted reproduction.

At the same time, higher cumulative doses did not meaningfully increase the probability of a live birth. In other words, additional clomiphene appeared to add risk without measurable benefit beyond a certain point—a classic case of diminishing returns.

"Women who received higher cumulative doses of clomiphene citrate experienced progressively greater risks of adverse pregnancy outcomes," says Associate Professor Sheree Boulet, the study’s lead author. "Increasing the dose did not significantly improve the chance of a live birth." Short, stark, and worrying.

The investigators also observed a creeping rise in spontaneous pregnancy loss as cumulative dose climbed. Stillbirth appeared more frequent at the highest exposures, though the researchers caution that so few women fell into that extreme category that the result lacked statistical certainty. Larger studies will be needed to confirm whether that signal is real.

This work builds on a longer program of research at Adelaide’s Robinson Research Institute. Earlier studies from the group flagged a doubled risk of neonatal death associated with clomiphene in certain contexts, and animal experiments have yielded similar concerns: in mice, higher doses correlated with fewer successful pregnancies and poorer fetal growth.

Current prescribing guidance reflects caution. U.S. labels recommend starting at 50 mg per day for five days, escalating only if ovulation fails, and advise against routinely exceeding 100 mg per day for five days. Long‑term cyclic use is generally discouraged beyond roughly six cycles. And importantly, if a woman ovulates at a given dose, upping that dose in subsequent cycles offers no proven advantage.

So where does this leave clinicians and patients? The study’s senior author, Professor Michael Davies, argues the findings underline variability in how women respond to clomiphene and the need for smarter, individualized dosing. "Our studies indicate women respond differently to clomiphene citrate," he notes, "and that increasing cumulative doses may increase risk without improving live birth chances." Simple enough, yet hard to operationalize in busy clinics.

Personalized fertility medicine is not a luxury; it’s a logical next step. If two patients start the same drug and one responds after a single short course while the other requires repeated cycles, a one‑size‑fits‑all escalation strategy may expose the latter to unnecessary harm. The results also serve as a reminder that newer ovulation‑inducing agents need the same rigorous safety scrutiny before they replace older drugs on the assumption of greater safety.

For patients facing infertility, the finding is practical: ask about total lifetime exposure to ovulation drugs. For clinicians, it’s a nudge to follow labeling carefully, weigh the risks of cumulative dosing, and consider alternative strategies when early cycles fail. Research will need to refine who benefits from continued clomiphene and who might be better served by a different approach—but until then, caution seems the wiser prescription.

Science rarely hands out tidy answers, but when more treatment stops helping and risks climb, maybe it’s time to rethink the next dose.